| Aug 9 |
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
|
| Aug 8 |
Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 7 |
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
|
| Aug 6 |
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
|
| Aug 6 |
Supernus: Q2 Earnings Snapshot
|
| Aug 6 |
Supernus Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook
|
| Aug 6 |
Supernus Announces Second Quarter 2024 Financial Results
|
| Aug 5 |
Supernus Pharmaceuticals Q2 2024 Earnings Preview
|
| Aug 1 |
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
|
